adriforant   

GtoPdb Ligand ID: 8985

Synonyms: PF 3893787 | PF-03893787 | ZPL-389 | ZPL-3893787 | ZPL389 | ZPL3893787
Compound class: Synthetic organic
Comment: Adriforant (ZPL-3893787) is an invesitgational immunomodulatory compound being developed by Ziarco Pharma (a Novartis subsidiary). Mechanistically it is a selective histamine H4 receptor antagonist.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 79.1
Molecular weight 262.19
XLogP 1.61
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES CNC1CCN(C1)c1cc(NCC2CC2)nc(n1)N
Isomeric SMILES CN[C@@H]1CCN(C1)c1cc(NCC2CC2)nc(n1)N
InChI InChI=1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1
InChI Key ISBHYKVAFKTATD-SNVBAGLBSA-N
Immunopharmacology Comments
ZPL-3893787 is an invesitgational selective histamine H4 receptor antagonist that is being developed for anti-inflammatory potential in the treatment of dermatological inflammation.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Completed Phase 2 trial in psoriasis (see NCT02618616).
Atopic dermatitis Disease Ontology: DOID:3310
OMIM: 603165
Completed Phase 2 trial in atopic dermatitis (see NCT02424253). Improvement in inflammatory AD lesions in response to ZPL-3893787 treatment in clinical trial was reported by Werrfel et al. (2018) 3